Insurance Disclaimer: Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have changed.
All data from NYU Health Sciences Library Faculty Bibliography — -
Pathologic response rate in HER2-positive locally advanced breast cancers treated with neoadjuvant trastuzumab and concurrent paclitaxel/radiotherapy
Adams, S; Hochman, T; Huppert, N; Dhage, S; Checka, C; Singh, B; Speyer, J L; Schneider, R; Goldberg, J D; Formenti, S
2012 20 May 2012;30(15):-, Journal of clinical oncology
— id: 249962, year: 2012, vol: 30, page: , stat: Journal Article,
Prospective Randomized Trial of Prone Accelerated Whole Breast Radiation Therapy With a Concurrent Daily Versus Weekly Boost to the Tumor Bed: Acute Toxicity
Osa, E. O.; Huppert, N.; Fenton-Kerimian, M.; Goldberg, J. D.; Jozsef, G.; DeWyngaert, K.; Formenti, S. C.
2012 NOV 1;84(3 S S):S84-S85, International journal of radiation oncology biology physics
— id: 204852, year: 2012, vol: 84, page: S84, stat: Journal Article,
The role of a prone setup in breast radiation therapy
Huppert, Nelly; Jozsef, Gabor; Dewyngaert, Keith; Formenti, Silvia Chiara
2011 ;1:31-31, Frontiers in oncology
— id: 169256, year: 2011,